Fig. 1From: Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrantA Overall survival in patients who received ribociclib plus fulvestrant as first-line therapy. B Overall survival in ITT population. C Overall survival in patients who received ribociclib plus fulvestrant as second-line therapyBack to article page